BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 15792801)

  • 1. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
    Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
    FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
    Hashimoto T; Kato M; Shimomura T; Kitamura N
    FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
    Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
    J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
    Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
    Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
    Parr C; Jiang WG
    Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
    Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
    Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
    Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
    J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
    Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
    J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
    Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
    Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human.
    Itoh H; Kataoka H; Hamasuna R; Kitamura N; Koono M
    Biochem Biophys Res Commun; 1999 Feb; 255(3):740-8. PubMed ID: 10049781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
    Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
    Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy.
    Watanabe T; Sakata Y; Matsubara S; Yamagishi T; Nagaike K; Kuwata T; Suzuki M
    J Obstet Gynaecol Res; 2006 Feb; 32(1):10-4. PubMed ID: 16445520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).
    Kataoka H; Itoh H; Hamasuna R; Meng JY; Koono M
    Hum Cell; 2001 Mar; 14(1):83-93. PubMed ID: 11436357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
    Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
    Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
    Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of hepatocyte growth factor activator inhibitor type 2 (HAI-2)-related small peptide (H2RSP): its nuclear localization and generation of chimeric mRNA transcribed from both HAI-2 and H2RSP genes.
    Itoh H; Kataoka H; Yamauchi M; Naganuma S; Akiyama Y; Nuki Y; Shimomura T; Miyazawa K; Kitamura N; Koono M
    Biochem Biophys Res Commun; 2001 Oct; 288(2):390-9. PubMed ID: 11606055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin.
    Fan B; Wu TD; Li W; Kirchhofer D
    J Biol Chem; 2005 Oct; 280(41):34513-20. PubMed ID: 16103126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
    Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
    Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1.
    Denda K; Shimomura T; Kawaguchi T; Miyazawa K; Kitamura N
    J Biol Chem; 2002 Apr; 277(16):14053-9. PubMed ID: 11805118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B.
    Reid JC; Bennett NC; Stephens CR; Carroll ML; Magdolen V; Clements JA; Hooper JD
    Biol Chem; 2016 Dec; 397(12):1299-1305. PubMed ID: 27533117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.